REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

Company Overview - REGENXBIO is a leading clinical-stage biotechnology company focused on gene therapy with a mission to improve lives through its innovative AAV Therapeutics [1] - The company was founded in 2009 and has developed a pipeline targeting retinal and rare diseases, including collaborations with AbbVie for ABBV-RGX-314 [1] Product Pipeline - REGENXBIO is advancing several AAV Therapeutics, including: - ABBV-RGX-314 for wet AMD and diabetic retinopathy [1] - RGX-202 for Duchenne muscular dystrophy [1] - RGX-121 for MPS II [1] - Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, which includes Novartis' ZOLGENSMA for spinal muscular atrophy [1] Treatment Potential - AAV Therapeutics are designed as one-time treatments, offering the potential to transform healthcare delivery for millions of patients [1]